BC
TEVA icon

Brinker Capital’s Teva Pharmaceuticals TEVA Stock Holding History

Brinker Capital’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-17,454
Closed -$307K – 1007
2017
Q3 		$307K Sell
17,454
-4,934
-22% -$111K 0.01% 805
2017
Q2 		$744K Sell
22,388
-352
-2% -$10.9K 0.03% 444
2017
Q1 		$730K Sell
22,740
-11,947
-34% -$408K 0.03% 481
2016
Q4 		$1.26M Buy
34,687
+26,296
+313% +$1.05M 0.07% 252
2016
Q3 		$386K Buy
8,391
+1,882
+29% +$98.2K 0.04% 233
2016
Q2 		$327K Buy
6,509
+1,652
+34% +$87.9K 0.03% 220
2016
Q1 		$259K Buy
+4,857
New +$285K 0.02% 229

Other funds holding TEVA

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
HCM
Highfields Capital Management Boston, Massachusetts $68.3M AUM 21.64% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
NC
Northern Cross Boston, Massachusetts $279M AUM 1.98% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $5.48B AUM 3.63% 1-Year Est. Return
Berkshire Hathaway
Berkshire Hathaway Omaha, Nebraska $299B AUM 27.55% 1-Year Est. Return
BC
Brahman Capital New York $275M AUM 18.08% 1-Year Est. Return

Brinker Capital's TEVA Position: Q4 2017 in Review

Brinker Capital sold out of Teva Pharmaceuticals (TEVA) in Q4 2017, closing a stake of 17,454 shares — an estimated $307K sold.

Brinker Capital first reported a position in TEVA in Q1 2016 and held it in 7 quarters. The position peaked at $1.26M in Q4 2016. 508 funds tracked by Wall St. Rank hold TEVA as of Q4 2017.

  • Brinker Capital reported no remaining Teva Pharmaceuticals position as of Q4 2017 after selling out during the quarter.
  • Brinker Capital sold 17,454 Teva Pharmaceuticals shares in Q4 2017, an estimated $307K.
  • Brinker Capital first reported a position in Teva Pharmaceuticals in Q1 2016 and held it in 7 quarters.
  • Brinker Capital's Teva Pharmaceuticals position peaked at $1.26M in Q4 2016.
  • 508 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q4 2017.

Based on Brinker Capital's 13F filing for Q4 2017, filed 14 Feb 2018.